Abstract:
UNLABELLED:Oral delayed-release mesalazine is an enteric-coated formulation which releases mesalazine in the terminal ileum and colon. Up to 74% of patients with mild to moderately active ulcerative colitis experience endoscopic or symptomatic improvement (including remission) or both when treated with oral delayed-release mesalazine 2.4 to 4.8 g/day. There is a trend towards a better response in patients receiving higher daily dosages of oral delayed-release mesalazine, especially in patients with active distal disease. In patients with left-sided ulcerative colitis, oral balsalazide 6.75 g/day appears to be more effective than oral delayed-release mesalazine 2.4 g/day, but a higher dosage of oral delayed-release mesalazine 4.8 g/day may provide additional benefit in these patients. Oral delayed-release mesalazine 0.8 to 4.4 g/day appears to be as effective as sulfasalazine 2 to 4 g/day, prolonged-release mesalazine 1.5 g/day or balsalazide 3 g/day in maintaining remission in patients with ulcerative colitis. The optimal dosage of oral delayed-release mesalazine for the maintenance of remission is unclear. However, oral delayed-release mesalazine 1.6 g/day with rectal mesalazine 4g, administered twice weekly, was more effective than oral drug alone in maintaining remission in patients at high risk of relapse. In patients with left-sided or distal disease oral olsalazine 1 g/day appeared to be superior to oral delayed-release mesalazine 1.2 g/day for maintenance of symptomatic remission. Limited data in patients with Crohn's disease have shown oral delayed-release mesalazine 0.4 to 4.8 g/day to be an effective therapy for active disease (remission in up to 45% of patients) and for quiescent disease (relapse in 34% of recipients over a duration of up to 12 months). Preliminary data indicate that oral delayed-release mesalazine 2.4 g/day is effective in preventing postoperative recurrence of Crohn's disease. Oral delayed-release mesalazine is effective and well tolerated in sulfasalazine-intolerant patients with ulcerative colitis or Crohn's disease. CONCLUSIONS:Oral delayed-release mesalazine is effective in patients with mild to moderately active or quiescent ulcerative colitis. Available data suggest that patients with left-sided or distal ulcerative colitis are likely to require higher daily dosages of oral delayed-release mesalazine or supplementation with rectal mesalazine. Oral delayed-release mesalazine also appears to be effective in active and quiescent Crohn's disease. The drug is well tolerated and it appears to be effective in sulfasalazine-intolerant patients.
journal_name
Drugsjournal_title
Drugsauthors
Prakash A,Markham Adoi
10.2165/00003495-199957030-00013subject
Has Abstractpub_date
1999-03-01 00:00:00pages
383-408issue
3eissn
0012-6667issn
1179-1950journal_volume
57pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::Heparin remains the most effective antithrombotic drug. It acts by combining with plasma antithrombin, thereby accelerating the neurtalisation of thrombin and other acitvated coagulation factors. Full-dose intravenous heparin is indicated in all cases of pulmonary embolism and established deep venous thrombosis, unles...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197713010-00005
更新日期:1977-01-01 00:00:00
abstract::Tipranavir (Aptivus) is a selective nonpeptidic HIV-1 protease inhibitor (PI) that is used in the treatment of treatment-experienced adults with HIV-1 infection. Tipranavir is administered orally twice daily and must be given in combination with low-dose ritonavir, which is used to boost its bioavailability. The durab...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200868100-00006
更新日期:2008-01-01 00:00:00
abstract::Subcutaneous dulaglutide (Trulicity®) is a once-weekly glucagon-like peptide-1 receptor agonist that is approved in numerous countries as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes (T2D). In the clinical trial and real-world settings, once-weekly subcutaneous dulaglutide, as monot...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01260-9
更新日期:2020-02-01 00:00:00
abstract::Insulin glargine 300 U/mL (Toujeo(®)) is a long-acting basal insulin analogue approved for the treatment of diabetes mellitus. Insulin glargine 300 U/mL has a more stable and prolonged pharmacokinetic/pharmacodynamic profile than insulin glargine 100 U/mL (Lantus(®)), with a duration of glucose-lowering activity excee...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0541-z
更新日期:2016-03-01 00:00:00
abstract::Glipizide is a 'second generation' oral hypoglycaemic agent similar in potency to glibenclamide. It is completely absorbed after oral administration and has a rapid onset of action, but the duration of its hypoglycaemic effect is shorter than that of glibenclamide. It is rapidly metabolised to inactive metabolites whi...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197918050-00001
更新日期:1979-11-01 00:00:00
abstract::The endothelium is involved in both the physiological regulation of vascular tone and the structural transformation of the vessel under pathological conditions. Under physiological conditions, endothelial cells continuously secrete nitric oxide (NO), which relaxes smooth muscle cells and ensures vessel patency. Damage...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199700531-00003
更新日期:1997-01-01 00:00:00
abstract::Suvorexant (Belsomra(®)), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been developed by Merck for the treatment of insomnia. Variations in the levels of the neuropeptides orexin A and orexin B have been linked to circadian rhythms and wakefulness. Orexin-producing neuro...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0294-5
更新日期:2014-10-01 00:00:00
abstract::Enasidenib (Idhifa®) is an oral isocitrate dehydrogenase-2 (IDH2) inhibitor developed by Celgene Corporation under a global, exclusive license from Agios Pharmaceuticals. Enasidenib has been approved in the USA for the treatment of adults with relapsed or refractory acute myeloid leukaemia (AML) and an IDH2 mutation a...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-017-0813-2
更新日期:2017-10-01 00:00:00
abstract::Delamanid (Deltyba(®)), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB) drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. It is approved in several countries, including Japan and those of the EU, for...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0331-4
更新日期:2015-01-01 00:00:00
abstract::A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections. 667 patients were randomly allocated to 1 of 3 different twice daily dosage regimens: 400 mg (245 patients), 600 mg (211) or 800 mg (211). The mean duration of tr...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198700341-00017
更新日期:1987-01-01 00:00:00
abstract::Amiodarone is a class III antiarrhythmic drug with sympatholytic properties, which prolongs the refractory period of all cardiac tissues, depresses sinus node automaticity and atrioventricular nodal conduction. It is active on all cardiac arrhythmias, its use being limited by the risk of side effects, mainly extracard...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199100412-00009
更新日期:1991-01-01 00:00:00
abstract::Remifentanil (Ultiva), a fentanyl derivative, is an ultra-short acting, nonspecific esterase-metabolised, selective mu-opioid receptor agonist, with a pharmacodynamic profile typical of opioid analgesic agents. Notably, the esterase linkage in remifentanil results in a unique and favourable pharmacokinetic profile for...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200565130-00007
更新日期:2005-01-01 00:00:00
abstract::Infections in burn patients continue to be the primary source of morbidity and mortality. Topical antimicrobial therapy remains the single most important component of wound care in hospitalised burn patients. The goal of prophylactic topical antimicrobial therapy is to control microbial colonisation and prevent burn w...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199040030-00004
更新日期:1990-09-01 00:00:00
abstract::Schizophrenia is a severe mental illness characterised by abnormalities of thought and perception that affects 1-2% of the population. Patients who experience a first episode of schizophrenia should be treated early and optimally with antipsychotic agents to lessen the morbidity of the initial episode and possibly imp...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200363210-00001
更新日期:2003-01-01 00:00:00
abstract::The discovery of at least 2 cyclo-oxygenase (COX) isoenzymes, referred to as COX-1 and COX-2, has updated our knowledge of nonsteroidal anti-inflammatory drugs (NSAIDs). This has lead investigators to reconsider what can be awaited from this class of drugs. The 2 COX isoenzymes share structural and enzymatic similarit...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199753040-00003
更新日期:1997-04-01 00:00:00
abstract::Gemfibrozil improves lipid and apolipoprotein profiles, particularly very low density lipoprotein (VLDL) triglyceride and high density lipoprotein (HDL) cholesterol levels, in patients with dyslipidaemia when administered at a total daily dose of 900 or 1200 mg. As demonstrated by the Helsinki Heart Study, these effec...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199651060-00009
更新日期:1996-06-01 00:00:00
abstract::Many drugs have a site of action within the inner ear. The list includes therapeutic, diagnostic and ototoxic agents. Therapeutic agents are most useful in cases of infections, endolymphatic hydrops, vascular insufficiency, vertigo of peripheral origin, autoimmune disease, otosclerosis (otospongiosis), sudden hearing ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198836060-00005
更新日期:1988-12-01 00:00:00
abstract::ROS1 gene rearrangements exist in 1-2% of non-small cell lung cancers, typically occurring in younger, never or light smokers with adenocarcinoma. ROS1 gene fusions are potent oncogenic drivers, the presence of which results in the susceptibility of tumours to ROS1-targeted therapy. Crizotinib was the first tyrosine k...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01164-3
更新日期:2019-08-01 00:00:00
abstract::Globally, tuberculosis (TB) and HIV interact in deadly synergy. The high burden of TB among HIV-infected individuals underlies the importance of TB diagnosis, treatment and prevention for clinicians involved in HIV care. Despite expanding access to antiretroviral therapy (ART) to treat HIV infection in resource-limite...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11591360-000000000-00000
更新日期:2011-06-18 00:00:00
abstract::Avapritinib (AYVAKIT™) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants. It is being developed by Blueprint Medicines for the treatment of gastrointestinal stromal tumours (GIST), solid tumours and systemic mastocytosis. Avapr...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01275-2
更新日期:2020-03-01 00:00:00
abstract::On the basis of well documented biochemical and pharmacological data about the influence of drug mediated enzyme induction on the biotransformation of natural and synthetic sex steroids, practical consequences for hormonal steroid contraception are described and discussed. Clinical reports dealing with this problem ar...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-197612060-00003
更新日期:1976-12-01 00:00:00
abstract:UNLABELLED:Darunavir is an oral nonpeptidic HIV-1 protease inhibitor (PI) that is used, together with a low boosting dose of ritonavir, as part of an antiretroviral therapy (ART) regimen in treatment-experienced and -naive patients with HIV-1 infection. Compared with early-generation PIs, boosted darunavir has a high g...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200969040-00007
更新日期:2009-01-01 00:00:00
abstract::Numerous intervention studies have clearly demonstrated the value of antihypertensive treatment. By lowering diastolic blood pressure 5 to 6mm Hg in middle-aged hypertensive patients, a 42% reduction in stroke morbidity and a 14% reduction in coronary heart disease morbidity can be obtained. Recently published large i...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199300462-00008
更新日期:1993-01-01 00:00:00
abstract::Insulin glulisine (Apidra) is a human insulin analogue approved for the improvement of glycaemic control in adults, adolescents and children with diabetes mellitus. It has similar binding properties, and is associated with a faster onset but similar level of glucose disposal, to regular human insulin (RHI). Insulin gl...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200969080-00006
更新日期:2009-05-29 00:00:00
abstract::A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been approved in the USA for the treatment of adults with chronic ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0558-3
更新日期:2016-04-01 00:00:00
abstract::Schistosomiasis, a grave and debilitating disease of socioeconomic importance, is increasing in incidence despite concerted efforts to control and contain the disease in all the endemic areas. While a multipronged method of control using health education, sanitation and snail control has been used, chemotherapy and ch...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199142030-00004
更新日期:1991-09-01 00:00:00
abstract:BACKGROUND:Opioid pharmacotherapies play an important role in the treatment of opioid-dependent women; however, very little is known about the safety of naltrexone in pregnant patients. OBJECTIVE:This study examined the obstetric health of opioid-dependent women who were treated with implant naltrexone during pregnanc...
journal_title:Drugs
pub_type: 杂志文章,meta分析
doi:10.1007/s40265-017-0762-9
更新日期:2017-07-01 00:00:00
abstract::It is well documented that long term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk of peptic ulcer and that gastroduodenal mucosal erosions can be demonstrated in volunteers within 1 week of treatment initiation. However, long term studies in nonsurgical patients have not documented g...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199200445-00006
更新日期:1992-01-01 00:00:00
abstract::In general, hepatic encephalopathy (HE) is defined as a brain dysfunction caused by liver insufficiency and/or portal-systemic blood shunting. This article relates to the so-called type C HE: that is, HE in patients with liver cirrhosis. It manifests as a wide spectrum of neurological or psychiatric abnormalities, ran...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-1018-z
更新日期:2019-02-01 00:00:00
abstract::Dementia is commonly diagnosed at a time of major domestic breakdown, when symptoms are severe and family and community patience has been eroded. In order to encourage early referral and identification of patients with treatable conditions, a Memory Clinic is held at the University Hospital in Cardiff. The clinic prov...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198700332-00016
更新日期:1987-01-01 00:00:00